The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
Shih-Lung Cheng,Ping-Huai Wang,Cheng-Yu Chang,Hsu-Hui Wang,Chung-Jen Wang,Kuan-Ming Chiu
DOI: https://doi.org/10.2147/dddt.s392708
2023-01-19
Abstract:Shih-Lung Cheng, 1, 2 Ping-Huai Wang, 1 Cheng-Yu Chang, 1 Hsu-Hui Wang, 1 Chung-Jen Wang, 1 Kuan-Ming Chiu 2, 3 1 Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan; 2 The Graduate Institute of Medicine, Yuan-Ze University, Taoyuan City, Taiwan; 3 Division of Cardiovascular Surgery, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan Correspondence: Kuan-Ming Chiu, Division of Cardiovascular Surgery, Far Eastern Memorial Hospital, No. 21, Section 2, Nanya S. Road, Banqiao District, New Taipei City, 220, Taiwan, Tel +886-2-89667000, Email Background: Molnupiravir (MOL) is an oral antiviral medication that has recently been treated for COVID-19. Objectively: We perform a prospective and observational study to elucidate the efficacy and safety of MOL in healthcare patients with COVID-19. Materials and Methods: A observational, non-randomized study of patients diagnosed with COVID-19 in 46 healthcare facilities and treated with MOL started within 5 days after the onset of signs or symptoms. We recorded data for all patients, including demographic data, clinical features, and symptoms. Treatment response was classified into cure, stable, hospitalization and death. Multivariate analysis was performed with stepwise logistic regression for hospitalization and death risk factors. Results: In total, 856 patients were diagnosed as having COVID-19 and treated with MOL during the study period. Of those, 496 patients (57.9%) were cured, 256 patients (29.9%) in stable condition, 104 patients (12.2%) hospitalized, and 22 patients (2.6%) died, respectively. There was significant effectiveness (87.8%) in COVID-19 patients using MOL. Multivariate analysis was performed to confirm the risk factors for hospitalization and death and included elder age (> 80 years old) (odds ratio (OR) 2.2, 95% confidence interval (CI): 1.1– 6.9), old cerebrovascular accident (CVA) (OR=4.1, 95% CI: 1.3– 9.9), the presence of diabetes mellitus (DM) (OR=2.6, 95% CI: 1.2– 9.1) and chronic respiratory diseases (OR=2.4, 95% (CI): 1.3– 8.1). Limitations: This is an observational study, neither randomized study nor control group study. Conclusion: Initial treatment with MOL has the treatment benefits and is well tolerated for patients with COVID-19 in healthcare facilities. Older age, old CVA, DM, and chronic respiratory diseases were independent risk factors for hospitalization and mortality. The results demonstrate there are important clinical benefits of MOL beyond the reduction in hospitalization or death for these patients with more comorbidities in Taiwan. Keywords: molnupiravir, COVID-19, healthcare facility, clinical benefit, hospitalization, comorbidity COVID-19 infection is currently affected among the general population in the world. This disease was first documented in Wuhan (China) in December 2019 and is due to SARS-CoV-2 (2019-nCoV) virus. COVID-19 symptoms included high body temperature, general malaise, sore throat, cough, shortness of breath, low energy status. In most infected people, the symptoms are mild, but in the elderly or those with multiple comorbidities it may complicate with severe pneumonia, acute respiratory distress syndrome, multi-organ failure, and death. 1 Adequate vaccines' administration is important for the prevention of severe COVID-19 development or mortality; however, the effective antiviral medications to combat this disease are not currently available. Patients with immunocompromised diseases could not be fully protected though got vaccinated, and existing vaccines may not be good protection against new SARS-CoV-2 variants. 2,3 Remdesivir, a new antiviral agent, has been demonstrated that there were beneficial effects in antiviral treatment 4 ; however, some studies have not documented its effectiveness on coronavirus therapy. Most important, the drug is expensive and can just be administered intravenously in a hospital facility. 4–6 For convenience and popularity, there is the need to develop simple oral anti-virus drugs available in most patients with COVID-19 infection. Three are new oral antiviral medications developed and have documented clinical effectiveness in recent studies. Among these oral medications, molnupiravir (MOL), a new orally active RdRp inhibitor with a excellent pharmacokinetic character, has demonstrated to have its ability to interfere SARS-COV-2 replication, and reduce viral load. 4 MOL has the unique agent with the isopropyl ester prodrug of the ribonucleoside analogue β-D-N4-hydroxycytidine (NHC). 7 Previous studies have found that MOL is -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal